ClinicalTrials.gg
CompletedNCT01568892VIKING-4Updated Jul 2, 2018Results posted

Study Assessing Dolutegravir in HIV-1 Infected Subjects With Virus Resistant to Raltegravir and/or Elivitegravir

A Phase 3 interventional study of Dolutegravir 50 mg twice daily and Dolutegravir placebo twice daily in HIV Infections, sponsored by ViiV Healthcare. Completed at 25 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-07-02.

Sponsored by ViiV Healthcare (part of GlaxoSmithKline) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 55 studies testing dolutegravir in HIV Infections — 7 open to participants now, 9 under way, 4 of them phase 3. Dolutegravir · HIV Infections.

Enrollment
46th of 55
30 · median 126
Started
2012
with 1 other
Phase 3
21 of 55
2 open now
Registered
10th of 55
by date
Lead sponsor
26 of 55
ViiV Healthcare

Among the 55 studies testing dolutegravir in HIV Infections, this one is the 46th largest by enrollment, is one of 2 that started in 2012, is one of 21 in phase 3, and was the 10th registered.

HIV Infections

4,737 studies on the registry are indexed under HIV Infections; 246 are open to participants now.

Browse HIV Infections studies →

Open to participants now

7 of the 55 studies testing dolutegravir in HIV Infections are open now, in 12 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About dolutegravir

Dolutegravir: first FDA approval 2013 (TIVICAY), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 55 studies testing dolutegravir in HIV Infections, or all of them as a file.
02

Study summary

Study ING116529 is a multicenter, randomized, study with an initial 7 day placebo- controlled, functional monotherapy phase to quantify the antiviral activity attributable to dolutegravir (DTG) in HIV-1 infected, ART-experienced adults who are experiencing virological failure on an Integrase inhibitor containing regimen (current RAL or ELV failures), with evidence of genotypic resistance to RAL or ELV at study entry. Thirty subjects will be randomized (1:1) to receive either DTG 50mg BID (Arm A) or Placebo (Arm B) with the current failing regimen for 7 days (RAL or ELV should be discontinued prior to dosing with DTG). At Day 8, subjects from both arms will enter an open label phase and receive open label DTG 50mg BID with an optimized background regimen containing at least one fully active drug.

Read the detailed description

Study ING116529 is a multicenter, randomized, study with an initial 7 day placebo-controlled, functional monotherapy phase to assess the antiviral activity and safety of a dolutegravir (DTG, GSK1349572) containing regimen in HIV-1 infected, ART-experienced adults with virological failure on an integrase inhibitor (INI) containing regimen.

Subjects must have evidence of genotypic resistance to raltegravir [RAL] or elvitegravir [ELV] at Screening and documented current or historical genotypic or phenotypic resistance to at least two other antiretroviral therapy drug classes.

The study is designed to provide an accurate measure of the intrinsic antiviral activity of DTG 50mg twice daily versus placebo both administered with the current failing regimen in a randomised double-blind phase to Day 8. This will be followed by an open label phase with all subjects receiving DTG 50mg twice daily with an optimized background regimen (containing at least one fully active drug) until subjects no longer derive clinical benefit or until DTG is locally available. Thirty subjects will be randomized (1:1) to receive either DTG 50mg BID (Arm A) or Placebo (Arm B) with the current failing regimen for 7 days (RAL or ELV should be discontinued prior to dosing at Day 1). At Day 8, subjects from both arms will enter an open label phase and receive open label DTG 50mg BID with an optimized background regimen containing at least one fully active drug The primary analysis will be conducted after the last subject enrolled has completed the randomised, double-blind phase at Day 8. Additional analyses may be performed prior to study closure when all ongoing subjects transition to locally available commercial DTG.

03

Conditions studied

  • HIV Infections

Browse trials for

Keywords

  • ART-experienced
  • GSK1349572
  • Integrase inhibitor resistance
  • Dolutegravir
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Screening plasma -1 RNA ≥1000 copies/mL
  • ART-experienced, INI-experienced, DTG naïve
  • Current virological failure on raltegravir (RAL) or elvitegravir (ELV) regimen
  • The subject's HIV-1 shows genotypic resistance to RAL or ELV at Screening
  • Subject has been on stable ART for at least one month prior to Screening and through Day 1(with exceptions for ETV, EFV and NVP that can be interrupted within 14 days of Day 1, see Exclusion Criterion)
  • Documented resistance to at least one drug from each of two or more of any approved classes of ART other than integrase inhibitors
  • Be able to receive at least one fully active drug as part of the OBR from Day 8
  • Women capable of becoming pregnant must use appropriate during the study (as defined by the protocol)
  • Willing and able to understand and provide signed and dated written prior to Screening.

Exclusion criteria

Exclusion Criteria:

  • Women who are pregnant or breast feeding
  • An active AIDS-defining condition at Screening (except cutaneous Kaposi's sarcoma not requiring systemic therapy or CD4+ \<200c/mm3)
  • Moderate to severe hepatic impairment as defined by classification
  • Anticipated need for therapy during the first 24 weeks of the study
  • Recent history (less than or equal to 3 months) of any upper or lower gastrointestinal bleed, with the exception of anal or rectal bleeding
  • Allergy or intolerance to the study drugs or their components or drugs of their class
  • within the past 6 months
  • Treatment with an -1 therapeutic vaccine within 90 days of Screening
  • Treatment with radiation therapy, cytotoxic chemotherapeutic agents or any immunomodulator within 28 days of Screening
  • Treatment with any agent, other than licensed ART, with documented in vitro/vivo activity against HIV-1 within 28 days of first dose of product (with the exception of entecavir if required for Hep B treatment)
  • Treatment with etravirine, efavirenz, or nevirapine within 14 days of Day 1(etravirine may be used if coadministered with lopinavir/ritonavir or darunavir/ritonavir)
  • Treatment with tipranivir/ritonavir, fosamprenavir, or fosamprenavir/ritonavir within 28 days prior to Screening
  • Exposure to an experimental drug or vaccine within either 28 days, 5 half-lives of the test agent, or twice the duration of the biological effect of the test agent, which ever is longer, prior to the first dose of IP.
  • Any acute or verified Grade 4 laboratory abnormality (with the exception of Grade 4 lipids) at Screening
  • > 5 times the (ULN) at Screening
  • ALT ≥ 3X ULN and > 1.5 X ULN (with 35% direct bilirubin) at Screening
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Single group
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    DTG 50 mg BID

    Subjects will receive dolutegravir (DTG) 50 milligrams (mg) twice daily (BID) and the components of their current failing antiretroviral regimen, except raltegravir or elvitegravir, for 7 days during the Double-blind (DB) Phase. From Day 8, all subjects will continue to receive DTG 50 mg BID with an optimized background regimen in the Open-label Phase.

    Drug: Dolutegravir 50 mg twice daily

  • Experimental
    Placebo BID in DB Phase; DTG 50 mg BID in Open-label Phase

    Subjects will receive matching placebo BID and the components of their current failing antiretroviral regimen, except raltegravir or elvitegravir, for 7 days during the DB Phase. From Day 8, all subjects will continue to receive DTG 50 mg BID with an optimized background regimen in the Open-label Phase.

    Drug: Dolutegravir 50 mg twice daily · Drug: Dolutegravir placebo twice daily

Interventions

  • Active dolutegravir plus failing background regimen (Day 1 to Day 7). Open label dolutegravir plus optimized background regimen (from Day 8)

    Also known as: GSK1349572

  • DrugDolutegravir placebo twice daily

    Dolutegravir placebo plus failing background regimen (Day 1 to Day 7)

    Also known as: GSK1349572 Placebo

06

What researchers measure

Primary outcomes

  1. Mean Change From Baseline in Plasma Human Immunodeficiency Virus Type 1 (HIV-1) Ribonucleic Acid (RNA) at Day 8

    Plasma samples were collected for quantitative HIV-1 RNA analysis at Baseline (Day 1) and Day 8. Change from Baseline was calculated as the value at Day 8 minus the value at Baseline (Day 1). The analysis was performed using statistical modeling correcting for Baseline plasma HIV-1 RNA, Baseline Dolutegravir (DTG) fold change (FC), the overall susceptibility score (OSS) of the failing regimen, and the interaction between DTG FC and treatment. Means and differences were calculated using the average Baseline DTG FC of the entire Intent-to-Treat Exposed (ITT-E) Population. The last observation carried forward with discontinuation equals Baseline (LOCFDB) dataset was used for the analysis. For the LOCFDB dataset, missing values were carried forward from the previous, non-missing, available on-treatment assessment, except formissing values due to premature withdrawal or Day 8 missing values, which had the Baseline value imputed.

    Time frame: Baseline and Day 8

Secondary outcomes

  1. Absolute Values in Plasma HIV-1 RNA Over Time

    Plasma samples were collected for quantitative HIV-1 RNA analysis at Baseline (Day 1), Day 8, Day 28, Week 8, Week 12, Week 16, Week 24, Week 32, Week 40, Week 48, Week 60, Week 72, and Week 84. NA indicates data was not available.

    Time frame: Baseline; Day 8; Day 28; Weeks 8, 12, 16, 24, 32, 40, 48, 60, 72, and 84

  2. Mean Change From Baseline in Plasma HIV-1 RNA Over Time

    Plasma samples were collected for quantitative HIV-1 RNA analysis at Baseline (Day 1), Day 8, Day 28, Week 8, Week 12, Week 16, Week 24, Week 32, Week 40, Week 48, Week 60, Week 72, and Week 84. Change from Baseline was calculated as the post-Baseline value minus the value at Baseline. NA indicates data was not available.

    Time frame: Baseline; Day 8; Day 28; Weeks 8, 12, 16, 24, 32, 40, 48, 60, 72, and 84

  3. Number of Participants With Plasma HIV-1 RNA <50 c/mL Over Time

    Plasma samples were collected for quantitative HIV-1 RNA analysis at Baseline (Day 1); Day 8; Day 28; Weeks 8, 12, 16, 24, 32, 40, and 48. Number of participants with plasma HIV-1 RNA level \<50 c/mL was obtained using Food and Drug Administration's (FDA's) snapshot algorithm, where all participants without HIV-1 RNA data at the visit of interest (due to missing data or discontinuation of investigational product prior to the visit window) were treated as non-responders. Also, participants who switched their concomitant antiretroviral therapy (ART) prior to the visit of interest as follows were also treated as non-responders: background ART substitutions not permitted per protocol; background ART substitutions permitted per protocol; however, the decision to switch is not documented as being before or at the first On-treatment visit after switching to optimized background regimen (OBR) (i.e. Day 28) where HIV-1 RNA is assessed.

    Time frame: Baseline; Day 8; Day 28; Weeks 8, 12, 16, 24, 32, 40 and 48

  4. Number of Participants With Plasma HIV-1 RNA <400 c/mL Over Time

    Plasma samples were collected for quantitative HIV-1 RNA analysis at Baseline (Day 1); Day 8; Day 28; Weeks 8, 12, 16, 24, 32, 40 and 48. Number of participants with plasma HIV-1 RNA level \<400 c/mL was obtained using FDA's snapshot algorithm, where all participants without HIV-1 RNA data at the visit of interest (due to missing data or discontinuation of investigational product prior to the visit window) were treated as non-responders. Also, participants who switch their concomitant ART prior to the visit of interest as follows were also treated as non-responders: background ART substitutions not permitted per protocol; background ART substitutions permitted per protocol; however the decision to switch is not documented as being before or at the first On-treatment visit after switching to OBR (i.e. Day 28) where HIV-1 RNA is assessed.

    Time frame: Baseline; Day 8; Day 28; Weeks 8, 12, 16, 24, 32, 40 and 48

  5. Absolute Values in Cluster of Differentiation 4+ (CD4+) Cell Counts Over Time

    Blood samples were collected for lymphocyte subset assessment by flow cytometry at Baseline; Day 8; Day 28; Weeks 8, 12, 16, 24, 32, 40, 48, 60, 72, and 84.

    Time frame: Baseline; Day 8; Day 28; Weeks 8, 12, 16, 24, 32, 40, 48, 60, 72, and 84

  6. Median Change From Baseline in CD4+ Cell Counts Over Time

    Blood samples were collected for lymphocyte subset assessment by flow cytometry at Baseline; Day 8; Day 28; Weeks 8, 12, 16, 24, 32, 40, 48, 60, 72, and 84. Change from Baseline was calculated as the post-Baseline value minus the value at Baseline.

    Time frame: Baseline; Day 8; Day 28; Weeks 8, 12, 16, 24, 32, 40, 48, 60, 72, and 84

  7. Absolute Values in Cluster of Differentiation 8+ (CD8+) Cell Counts Over Time

    Blood samples were collected for lymphocyte subset assessment by flow cytometry at Baseline; Day 28; and Weeks 12, 24, and 48.

    Time frame: Baseline; Day 28; Weeks 12, 24, and 48

  8. Median Change From Baseline in CD8+ Cell Counts Over Time

    Blood samples were collected for lymphocyte subset assessment by flow cytometry at Baseline; Day 28; and Weeks 12, 24, and 48. Change from Baseline was calculated as the post-Baseline value minus the value at Baseline.

    Time frame: Baseline; Day 28; Weeks 12, 24, and 48

  9. Number of Participants With the Indicated Type of HIV-1 Disease Progression (Acquired Immunodeficiency Syndrome [AIDS] or Death [DT])

    The number of participants with HIV-1 disease progression (AIDS or death) was assessed per the Centers for Disease Control and Prevention (CDC) 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. The CDC classifies HIV infection as Category A (participants with asymptomatic HIV infection, acute HIV infection with accompanying illness, or persistent generalized lymphadenopathy), Category B (participants with symptomatic non-AIDS condition, i.e., conditions that are attributed to HIV infection or are indicative of a defect in cell-mediated immunity; or conditions are considered by physicians to have a clinical course or to require management that is complicated by HIV infection), and Category C (includes AIDS indicator conditions as defined by diagnostic or presumptive measures).

    Time frame: From the day of the first dose of study drug until early withdrawal or the Week 48 analysis cut-off date (median of 55 study weeks)

  10. Number of Participants With Any Adverse Event (Serious and Non-serious) of the Indicated Grade

    An adverse event (AE) is defined as any untoward medical occurrence in a participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. A serious adverse event (SAE) is defined as any untoward medical occurrence that, at any dose: results in death; is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity; or is a congenital anomaly/birth defect. Medical or scientific judgment should be exercised in other situations. Adverse events were graded for severity according to the Division of AIDS (DAIDS) toxicity scales as: Grade 1 (mild), Grade 2 (moderate), Grade 3 (severe), or Grade 4 (potentially life threatening).

    Time frame: From the first dose of study medication until early withdrawal or through the Week 48 analysis data cut-off date (median of 55 study weeks)

  11. Number of Participants With the Maximum Post-Baseline-emergent Clinical Chemistry Toxicities of the Indicated Grade

    Participants with post-Baseline-emergent clinical chemistry toxicities were analyzed. Clinical chemistry toxicities were graded for severity according to the DAIDS toxicity scales as: Grade 1 (mild), Grade 2 (moderate), Grade 3 (severe), or Grade 4 (potentially life threatening).

    Time frame: From the first dose of study medication until early withdrawal or through the Week 48 analysis data cut-off date (median of 55 study weeks)

  12. Number of Participants With the Maximum Post-Baseline-emergent Hematology Toxicities of the Indicated Grade

    Participants with post-Baseline-emergent hematology toxicities were analyzed. Hematology toxicities were graded for severity according to the DAIDS toxicity scales as: Grade 1 (mild), Grade 2 (moderate), Grade 3 (severe), or Grade 4 (potentially life threatening).

    Time frame: From the first dose of study medication until early withdrawal or through the Week 48 analysis data cut-off date (median of 55 study weeks)

  13. AUC(0-tau) of DTG

    The area under the time concentration curve over the dosing interval (AUC\[0-tau\]) of DTG was assessed by a population pharmacokinetic (PK) modeling approach using pooled DTG PK data from multiple studies. Blood samples for the determination of plasma DTG concentration were collected at the following time points: pre-dose and 1-3 hours post-dose on Day 8; pre-dose and within a post-dose window (1-3 hours or 4-12 hours) on Day 28 and Week 24. For Day 8 PK, only samples collected from participants randomized to the active DTG arm were analyzed.

    Time frame: Day 8, Day 28, and Week 24

  14. Cmax of DTG

    The maximal concentration (Cmax) of DTG was assessed by a population PK modeling approach using pooled DTG PK data from multiple studies. Blood samples for the determination of plasma DTG concentration were collected at the following time points: pre-dose and 1-3 hours post-dose on Day 8; pre-dose and within a post-dose window (1-3 hours or 4-12 hours) on Day 28 and Week 24. For Day 8 PK, only samples collected from participants randomized to the active DTG arm were analyzed.

    Time frame: Day 8, Day 28, and Week 24

  15. Plasma DTG Pre-dose Concentration (C0) at Day 8, Day 28, and Week 24; and Average DTG C0 (C0 Avg) at Week 24

    Blood samples for the determination of plasma DTG pre-dose concentration were collected pre-dose on Day 8, Day 28, and Week 24. For Day 8 PK, only samples collected from participants randomized to the active DTG arm were analyzed. C0 Avg was calculated at Week 24 as the mean of the concentration at Day 8, Day 28, and Week 24.

    Time frame: Day 8, Day 28, and Week 24

  16. Number of Participants With the Indicated Treatment-emergent Integrase (IN) Mutations Detected at the Time of Defined Virologic Failure (PDVF), as a Measure of Genotypic Resistance

    For participants meeting one of the criteria for PDVF, plasma samples collected at the time point of virologic failure were tested to evaluate any potential genotypic and/or phenotypic evolution of resistance. PDVF was defined as (A) Virologic Non-response: a decrease in plasma HIV-1 RNA of \<1 log10 copies/mL by Day 28, with subsequent confirmation, unless plasma HIV-1 RNA is \<400 copies/mL; confirmed plasma HIV-1 RNA levels \>=400 copies/mL on or after Week 24 or (B) Virologic Rebound: confirmed rebound in plasma HIV-1 RNA levels to \>=400 copies/mL after prior confirmed suppression to \<400 copies/mL; confirmed plasma HIV-1 RNA levels \>1 log10 copies/mL above the nadir value, where nadir is \>=400 copies/mL.Treatment-emergent IN mutations are those detected at the time of PDVF but not at Baseline.

    Time frame: From the first dose of study medication until early withdrawal or through the Week 48 analysis data cut-off date (median of 55 study weeks)

  17. Number of Participants With the Indicated Fold Increase in Fold Change (FC) in the 50% Inhibitory Concentration Relative to Wild-type Virus for DTG (i.e. PDVF FC/Baseline FC Ratio) at the Time of PDVF, as a Measure of Phenotypic Resistance

    For participants meeting one of the criteria for PDVF, plasma samples collected at the time point of virologic failure were tested to evaluate any potential genotypic and/or phenotypic evolution of resistance. The FC in IC50 (50% inhibitory concentration) for DTG relative to wild-type virus was determined for virus isolated at Baseline and at the time of PDVF. The number of participants with the indicated change (ratio) in the two values at the time of PDVF is presented. PDVF was defined as (A) Virologic Non-response: a decrease in plasma HIV-1 RNA of \<1 log10 copies/mL by Day 28, with subsequent confirmation, unless plasma HIV-1 RNA is \<400 copies/mL; confirmed plasma HIV-1 RNA levels \>=400 copies/mL on or after Week 24 or (B) Virologic Rebound: confirmed rebound in plasma HIV-1 RNA levels to \>=400 copies/mL after prior confirmed suppression to \<400 copies/mL; confirmed plasma HIV-1 RNA levels \>1 log10 copies/mL above the nadir value, where nadir is \>=400 copies/mL.

    Time frame: From the first dose of study medication until early withdrawal or through the Week 48 analysis data cut-off date (median of 55 study weeks)

  18. Number of Participants Who Discontinued Study Treatment Due to AEs

    The number of participants who permanently discontinued study treatment due to AEs is presented.

    Time frame: From the first dose of study medication until early withdrawal or through the Week 48 analysis data cut-off date (median of 55 study weeks)

  19. Number of Participants With Clinically Significant Electrocardiogram (ECG) Findings

    Twelve lead ECG was performed using an automated ECG machine. The number of participants with abnormal-clinically significant ECG findings at any time on-treatment is reported.

    Time frame: Up to Week 24

  20. Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)

    Vital signs including SBP and DBP were measured at Baseline, Week 24 and Week 48. Baseline was defined as the last pre-treatment value. Change from Baseline was calculated as the post-Baseline value minus the value at Baseline.

    Time frame: Baseline and Weeks 24 and 48

  21. Change From Baseline in Heart Rate

    Vital signs including heart rate was measured at Baseline, Week 24 and Week 48. Baseline was defined as the last pre-treatment value. Change from Baseline was calculated as the post-Baseline value minus the value at Baseline.

    Time frame: Baseline and Weeks 24 and 48

  22. Change From Baseline in Albumin Level

    Blood samples were collected for the analysis of clinical chemistry parameters such as albumin. Baseline was defined as the last pre-treatment value. Change from Baseline was calculated as the post-Baseline value minus the value at Baseline.

    Time frame: Baseline, Week 24 and 48

  23. Change From Baseline in Alkaline Phosphatase (ALP), Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST) and Creatine Kinase

    Blood samples were collected for the analysis of clinical chemistry parameters such as ALP, ALT, AST and creatine kinase. Baseline was defined as the last pre-treatment value. Change from Baseline was calculated as the post-Baseline value minus the value at Baseline. NA indicates data was not available.

    Time frame: Baseline, Day 8, Day 28, Weeks 8, 12, 16, 24, 32, 40, 48, 60, 72 and 84

  24. Change From Baseline in Total Bilirubin (T. Bil) and Creatinine Levels

    Blood samples were collected for the analysis of clinical chemistry parameters such as T. Bil and creatinine. Baseline was defined as the last pre-treatment value. Change from Baseline was calculated as the post-Baseline value minus the value at Baseline. NA indicates data was not available.

    Time frame: Baseline, Day 8, Day 28, Weeks 8, 12, 16, 24, 32, 40, 48, 60, 72 and 84

  25. Change From Baseline in Cholesterol, Chloride, Carbon Dioxide (CO2)/Bicarbonate (HCO3), Glucose, High Density Lipoprotein Cholesterol, Potassium, Low Density Lipoprotein (LDL) Cholesterol, Sodium, Phosphorus, Triglycerides and Urea/Blood Urea Nitrogen

    Blood samples were collected for the analysis of clinical chemistry parameters such as cholesterol, chloride, CO2/HCO3, glucose, high density lipoprotein (HDL) cholesterol, potassium, LDL cholesterol, sodium, phosphorus inorganic, triglycerides and urea/blood urea nitrogen (BUN). Baseline was defined as the last pre-treatment value. Change from Baseline was calculated as the post-Baseline value minus the value at Baseline. NA indicates data was not available.

    Time frame: Baseline, Day 8, Day 28, Weeks 8, 12, 16, 24, 32, 40, 48, 60, 72 and 84

  26. Change From Baseline in Creatinine Clearance

    Creatinine clearance was calculated using Cockcroft-Gault formula. Baseline was defined as the last pre-treatment value. Change from Baseline was calculated as the post-Baseline value minus the value at Baseline.

    Time frame: Baseline, Day 8, Day 28, Week 8, Week 16, Week 24, Week 32 and Week 48

  27. Change From Baseline in Lipase Levels

    Blood samples were collected for the analysis of clinical chemistry parameters such as lipase level. Baseline was defined as the last pre-treatment value. Change from Baseline was calculated as the post-Baseline value minus the value at Baseline. NA indicates data was not available.

    Time frame: Baseline, Day 8, Day 28, Weeks 8, 12, 16, 24, 32, 40, 48, 60, 72 and 84

  28. Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Total Neutrophils, Platelet and White Blood Cell (WBC) Count

    Blood samples were collected for the analysis of hematology parameters such as basophils, eosinophils. Baseline was defined as the last pre-treatment value. Change from Baseline was calculated as the post-Baseline value minus the value at Baseline. NA indicates data was not available.

    Time frame: Baseline, Day 8, Day 28, Weeks 8, 12, 16, 24, 32, 40, 48, 60, 72 and 84

  29. Change From Baseline in Hemoglobin Level

    Blood samples were collected for the analysis of hematology parameters such as hemoglobin. Baseline was defined as the last pre-treatment value. Change from Baseline was calculated as the post-Baseline value minus the value at Baseline. NA indicates data was not available.

    Time frame: Baseline, Day 8, Day 28, Weeks 8, 12, 16, 24, 32, 40, 48, 60, 72 and 84

  30. Change From Baseline in Hematocrit Level

    Blood samples were collected for the analysis of hematology parameters such as hematocrit level. Baseline was defined as the last pre-treatment value. Change from Baseline was calculated as the post-Baseline value minus the value at Baseline. NA indicates data was not available.

    Time frame: Baseline, Day 8, Day 28, Weeks 8, 12, 16, 24, 32, 40, 48, 60, 72 and 84

  31. Change From Baseline in Mean Corpuscle Volume

    Blood samples were collected for the analysis of hematology parameters such as mean corpuscle volume. Baseline was defined as the last pre-treatment value. Change from Baseline was calculated as the post-Baseline value minus the value at Baseline. NA indicates data was not available.

    Time frame: Baseline, Day 8, Day 28, Weeks 8, 12, 16, 24, 32, 40, 48, 60, 72 and 84

  32. Change From Baseline in Red Blood Cell Count

    Blood samples were collected for the analysis of hematology parameters such as RBC. Baseline was defined as the last pre-treatment value. Change from Baseline was calculated as the post-Baseline value minus the value at Baseline. NA indicates data was not available.

    Time frame: Baseline, Day 8, Day 28, Weeks 8, 12, 16, 24, 32, 40, 48, 60, 72 and 84

07

Results

Posted Feb 19, 2014

Participant flow

Double-blind Phase
Participant flow — Double-blind Phase
MilestoneDTG 50 mg BIDPlacebo BID in DB Phase; DTG 50 mg BID in Open-label Phase
Started1416
Completed1416
Not completed00
Open-label Phase
Participant flow — Open-label Phase
MilestoneDTG 50 mg BIDPlacebo BID in DB Phase; DTG 50 mg BID in Open-label Phase
Started1316
Completed713
Not completed63
Withdrew: Adverse event20
Withdrew: Lack of efficacy42
Withdrew: Lost to follow-up01

Outcome measures

PrimaryMean Change From Baseline in Plasma Human Immunodeficiency Virus Type 1 (HIV-1) Ribonucleic Acid (RNA) at Day 8

Plasma samples were collected for quantitative HIV-1 RNA analysis at Baseline (Day 1) and Day 8. Change from Baseline was calculated as the value at Day 8 minus the value at Baseline (Day 1). The analysis was performed using statistical modeling correcting for Baseline plasma HIV-1 RNA, Baseline Dolutegravir (DTG) fold change (FC), the overall susceptibility score (OSS) of the failing regimen, and the interaction between DTG FC and treatment. Means and differences were calculated using the average Baseline DTG FC of the entire Intent-to-Treat Exposed (ITT-E) Population. The last observation carried forward with discontinuation equals Baseline (LOCFDB) dataset was used for the analysis. For the LOCFDB dataset, missing values were carried forward from the previous, non-missing, available on-treatment assessment, except formissing values due to premature withdrawal or Day 8 missing values, which had the Baseline value imputed.

Time frame:
Baseline and Day 8
Reported as:
Least squares mean · Log 10 copies per milliliter (c/mL)
Mean Change From Baseline in Plasma Human Immunodeficiency Virus Type 1 (HIV-1) Ribonucleic Acid (RNA) at Day 8
Log 10 copies per milliliter (c/mL)DTG 50 mg BIDPlacebo BID in DB Phase; DTG 50 mg BID in Open-label Phase
Mean Change From Baseline in Plasma Human Immunodeficiency Virus Type 1 (HIV-1) Ribonucleic Acid (RNA) at Day 8-1.06 ± 0.1680.10 ± 0.183
Statistical analysis
  • DTG 50 mg BID vs Placebo BID in DB Phase; DTG 50 mg BID in Open-label Phase · ANCOVA · p = <0.001 · Mean difference (net): -1.16 · 95% CI -1.52 to -0.80The estimated value represents the adjusted mean difference between the two treatment arms.
SecondaryAbsolute Values in Plasma HIV-1 RNA Over Time

Plasma samples were collected for quantitative HIV-1 RNA analysis at Baseline (Day 1), Day 8, Day 28, Week 8, Week 12, Week 16, Week 24, Week 32, Week 40, Week 48, Week 60, Week 72, and Week 84. NA indicates data was not available.

Time frame:
Baseline; Day 8; Day 28; Weeks 8, 12, 16, 24, 32, 40, 48, 60, 72, and 84
Reported as:
Mean · Log10 c/mL
Absolute Values in Plasma HIV-1 RNA Over Time
Log10 c/mLDTG 50 mg BIDPlacebo BID in DB Phase; DTG 50 mg BID in Open-label Phase
Baseline, n=14, 164.02 ± 0.9404.42 ± 0.760
Day 8, n=14, 162.95 ± 0.7904.39 ± 0.844
Day 28, n=13, 162.14 ± 0.7722.30 ± 1.054
Week 8, n=11, 162.35 ± 0.8512.10 ± 0.913
Week 12, n=12, 142.51 ± 1.0482.27 ± 1.179
Week 16, n=12, 162.57 ± 1.0932.18 ± 1.098
Week 24, n=11, 152.65 ± 1.2191.88 ± 0.654
Week 32, n=11, 142.72 ± 1.1761.81 ± 0.664
Week 40, n=7, 122.35 ± 1.1691.68 ± 0.133
Week 48, n=8, 132.47 ± 1.0371.62 ± 0.088
Week 60, n=5, 122.15 ± 1.0131.67 ± 0.150
Week 72, n=3, 42.35 ± 1.3121.62 ± 0.054
Week 84, n=0, 1—1.59 ± NA
SecondaryMean Change From Baseline in Plasma HIV-1 RNA Over Time

Plasma samples were collected for quantitative HIV-1 RNA analysis at Baseline (Day 1), Day 8, Day 28, Week 8, Week 12, Week 16, Week 24, Week 32, Week 40, Week 48, Week 60, Week 72, and Week 84. Change from Baseline was calculated as the post-Baseline value minus the value at Baseline. NA indicates data was not available.

Time frame:
Baseline; Day 8; Day 28; Weeks 8, 12, 16, 24, 32, 40, 48, 60, 72, and 84
Reported as:
Mean · Log10 c/mL
Mean Change From Baseline in Plasma HIV-1 RNA Over Time
Log10 c/mLDTG 50 mg BIDPlacebo BID in DB Phase; DTG 50 mg BID in Open-label Phase
Baseline, n=14, 164.02 ± 0.9404.42 ± 0.760
Day 8, n=14, 16-1.07 ± 0.683-0.03 ± 0.262
Day 28, n=13, 16-1.87 ± 0.898-2.12 ± 1.111
Week 8, n=11, 16-1.89 ± 0.890-2.32 ± 1.112
Week 12, n=12, 14-1.54 ± 1.022-2.02 ± 1.245
Week 16, n=12, 16-1.48 ± 1.101-2.24 ± 1.180
Week 24, n=11, 15-1.38 ± 1.151-2.53 ± 1.033
Week 32, n=11, 14-1.31 ± 1.059-2.62 ± 0.931
Week 40, n=7, 12-1.48 ± 1.445-2.70 ± 0.843
Week 48, n=8, 13-1.34 ± 1.235-2.77 ± 0.881
Week 60, n=5, 12-1.91 ± 1.400-2.71 ± 0.863
Week 72, n=3, 4-2.08 ± 1.311-3.31 ± 0.968
Week 84, n=0, 1—-3.75 ± NA
SecondaryNumber of Participants With Plasma HIV-1 RNA <50 c/mL Over Time

Plasma samples were collected for quantitative HIV-1 RNA analysis at Baseline (Day 1); Day 8; Day 28; Weeks 8, 12, 16, 24, 32, 40, and 48. Number of participants with plasma HIV-1 RNA level \<50 c/mL was obtained using Food and Drug Administration's (FDA's) snapshot algorithm, where all participants without HIV-1 RNA data at the visit of interest (due to missing data or discontinuation of investigational product prior to the visit window) were treated as non-responders. Also, participants who switched their concomitant antiretroviral therapy (ART) prior to the visit of interest as follows were also treated as non-responders: background ART substitutions not permitted per protocol; background ART substitutions permitted per protocol; however, the decision to switch is not documented as being before or at the first On-treatment visit after switching to optimized background regimen (OBR) (i.e. Day 28) where HIV-1 RNA is assessed.

Time frame:
Baseline; Day 8; Day 28; Weeks 8, 12, 16, 24, 32, 40 and 48
Reported as:
Count of participants · Participants
Number of Participants With Plasma HIV-1 RNA <50 c/mL Over Time
ParticipantsDTG 50 mg BIDPlacebo BID in DB Phase; DTG 50 mg BID in Open-label Phase
Baseline00
Day 810
Day 2866
Week 859
Week 1268
Week 1658
Week 2468
Week 3249
Week 4047
Week 4839
SecondaryNumber of Participants With Plasma HIV-1 RNA <400 c/mL Over Time

Plasma samples were collected for quantitative HIV-1 RNA analysis at Baseline (Day 1); Day 8; Day 28; Weeks 8, 12, 16, 24, 32, 40 and 48. Number of participants with plasma HIV-1 RNA level \<400 c/mL was obtained using FDA's snapshot algorithm, where all participants without HIV-1 RNA data at the visit of interest (due to missing data or discontinuation of investigational product prior to the visit window) were treated as non-responders. Also, participants who switch their concomitant ART prior to the visit of interest as follows were also treated as non-responders: background ART substitutions not permitted per protocol; background ART substitutions permitted per protocol; however the decision to switch is not documented as being before or at the first On-treatment visit after switching to OBR (i.e. Day 28) where HIV-1 RNA is assessed.

Time frame:
Baseline; Day 8; Day 28; Weeks 8, 12, 16, 24, 32, 40 and 48
Reported as:
Count of participants · Participants
Number of Participants With Plasma HIV-1 RNA <400 c/mL Over Time
ParticipantsDTG 50 mg BIDPlacebo BID in DB Phase; DTG 50 mg BID in Open-label Phase
Baseline20
Day 840
Day 28912
Week 8713
Week 12710
Week 16712
Week 24611
Week 32610
Week 40510
Week 48610
SecondaryAbsolute Values in Cluster of Differentiation 4+ (CD4+) Cell Counts Over Time

Blood samples were collected for lymphocyte subset assessment by flow cytometry at Baseline; Day 8; Day 28; Weeks 8, 12, 16, 24, 32, 40, 48, 60, 72, and 84.

Time frame:
Baseline; Day 8; Day 28; Weeks 8, 12, 16, 24, 32, 40, 48, 60, 72, and 84
Reported as:
Median · Cells per cubic millimeters
Absolute Values in Cluster of Differentiation 4+ (CD4+) Cell Counts Over Time
Cells per cubic millimetersDTG 50 mg BIDPlacebo BID in DB Phase; DTG 50 mg BID in Open-label Phase
Baseline, n=14, 16163.5 (111.0 to 231.0)90.5 (46.0 to 267.5)
Day 8, n=14, 15198.5 (154.0 to 239.0)102.0 (50.0 to 310.0)
Day 28, n=13, 16174.0 (168.0 to 335.0)234.0 (114.5 to 303.5)
Week 8, n=11, 16211.0 (71.0 to 401.0)228.0 (124.0 to 357.5)
Week 12, n=12, 14223.5 (115.0 to 345.5)217.5 (121.0 to 333.0)
Week 16, n=12, 16241.0 (107.5 to 382.5)262.5 (132.5 to 436.5)
Week 24, n=11, 15232.0 (116.0 to 509.0)242.0 (194.0 to 399.0)
Week 32, n=11, 14213.0 (91.0 to 489.0)326.0 (229.0 to 542.0)
Week 40, n=8, 12299.5 (212.5 to 566.5)328.0 (204.5 to 508.0)
Week 48, n=8, 13328.0 (263.0 to 526.5)370.0 (231.0 to 457.0)
Week 60, n=5, 12321.0 (234.0 to 328.0)333.0 (217.5 to 541.0)
Week 72, n=3, 4321.0 (261.0 to 465.0)299.5 (231.5 to 349.0)
Week 84, n=0, 1—368.0 (368.0 to 368.0)
SecondaryMedian Change From Baseline in CD4+ Cell Counts Over Time

Blood samples were collected for lymphocyte subset assessment by flow cytometry at Baseline; Day 8; Day 28; Weeks 8, 12, 16, 24, 32, 40, 48, 60, 72, and 84. Change from Baseline was calculated as the post-Baseline value minus the value at Baseline.

Time frame:
Baseline; Day 8; Day 28; Weeks 8, 12, 16, 24, 32, 40, 48, 60, 72, and 84
Reported as:
Median · Cells per cubic millimeters
Median Change From Baseline in CD4+ Cell Counts Over Time
Cells per cubic millimetersDTG 50 mg BIDPlacebo BID in DB Phase; DTG 50 mg BID in Open-label Phase
Baseline, n=14, 16163.5 (111.0 to 231.0)90.5 (46.0 to 267.5)
Day 8, n=14, 157.0 (0.0 to 94.0)0.0 (-12.0 to 24.0)
Day 28, n=13, 1614.0 (6.0 to 68.0)68.5 (5.0 to 140.5)
Week 8, n=11, 1634.0 (10.0 to 96.0)87.5 (9.5 to 138.5)
Week 12, n=12, 1449.0 (-5.0 to 83.0)79.0 (1.0 to 121.0)
Week 16, n=12, 1676.5 (3.0 to 151.0)70.0 (20.5 to 235.0)
Week 24, n=11, 1539.0 (0.0 to 134.0)117.0 (23.0 to 163.0)
Week 32, n=11, 1448.0 (0.0 to 198.0)135.5 (58.0 to 271.0)
Week 40, n=8, 1290.5 (45.0 to 226.5)125.5 (50.0 to 244.5)
Week 48, n=8, 13115.0 (96.0 to 226.5)156.0 (68.0 to 293.0)
Week 60, n=5, 12170.0 (65.0 to 210.0)146.0 (73.5 to 242.0)
Week 72, n=3, 4163.0 (96.0 to 354.0)174.0 (147.0 to 225.0)
Week 84, n=0, 1—269.0 (269.0 to 269.0)
SecondaryAbsolute Values in Cluster of Differentiation 8+ (CD8+) Cell Counts Over Time

Blood samples were collected for lymphocyte subset assessment by flow cytometry at Baseline; Day 28; and Weeks 12, 24, and 48.

Time frame:
Baseline; Day 28; Weeks 12, 24, and 48
Reported as:
Median · Cells per cubic millimeter
Absolute Values in Cluster of Differentiation 8+ (CD8+) Cell Counts Over Time
Cells per cubic millimeterDTG 50 mg BIDPlacebo BID in DB Phase; DTG 50 mg BID in Open-label Phase
Baseline, n=14, 16896.0 (589.0 to 1689.0)808.5 (436.5 to 1221.0)
Day 28, n=13, 161135.0 (598.0 to 1741.0)973.0 (675.0 to 1322.0)
Week 12, n=11, 141198.0 (591.0 to 1977.0)1184.0 (860.0 to 1711.0)
Week 24, n=11, 151160.0 (526.0 to 1908.0)1323.0 (969.0 to 1622.0)
Week 48, n=6, 121295.0 (837.0 to 1818.0)1147.0 (753.0 to 1570.0)
SecondaryMedian Change From Baseline in CD8+ Cell Counts Over Time

Blood samples were collected for lymphocyte subset assessment by flow cytometry at Baseline; Day 28; and Weeks 12, 24, and 48. Change from Baseline was calculated as the post-Baseline value minus the value at Baseline.

Time frame:
Baseline; Day 28; Weeks 12, 24, and 48
Reported as:
Median · Cells per cubic millimeter
Median Change From Baseline in CD8+ Cell Counts Over Time
Cells per cubic millimeterDTG 50 mg BIDPlacebo BID in DB Phase; DTG 50 mg BID in Open-label Phase
Baseline, n=14, 16896.0 (589.0 to 1689.0)808.5 (436.5 to 1221.0)
Day 28, n=13, 16227.0 (-135.0 to 301.0)177.0 (51.0 to 278.5)
Week 12, n=11, 14151.0 (-150.0 to 379.0)288.0 (193.0 to 484.0)
Week 24, n=11, 1579.0 (-183.0 to 269.0)543.0 (35.0 to 930.0)
Week 48, n=6, 1288.0 (-19.0 to 179.0)124.0 (-102.5 to 238.5)
SecondaryNumber of Participants With the Indicated Type of HIV-1 Disease Progression (Acquired Immunodeficiency Syndrome [AIDS] or Death [DT])

The number of participants with HIV-1 disease progression (AIDS or death) was assessed per the Centers for Disease Control and Prevention (CDC) 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. The CDC classifies HIV infection as Category A (participants with asymptomatic HIV infection, acute HIV infection with accompanying illness, or persistent generalized lymphadenopathy), Category B (participants with symptomatic non-AIDS condition, i.e., conditions that are attributed to HIV infection or are indicative of a defect in cell-mediated immunity; or conditions are considered by physicians to have a clinical course or to require management that is complicated by HIV infection), and Category C (includes AIDS indicator conditions as defined by diagnostic or presumptive measures).

Time frame:
From the day of the first dose of study drug until early withdrawal or the Week 48 analysis cut-off date (median of 55 study weeks)
Reported as:
Count of participants · Participants
Number of Participants With the Indicated Type of HIV-1 Disease Progression (Acquired Immunodeficiency Syndrome [AIDS] or Death [DT])
ParticipantsDTG 50 mg BIDPlacebo BID in DB Phase; DTG 50 mg BID in Open-label Phase
From CDC Class A to CDC Class C00
From CDC Class B to CDC Class C00
From CDC Class C to new CDC Class C00
From CDC Class A, B, or C to Death20
SecondaryNumber of Participants With Any Adverse Event (Serious and Non-serious) of the Indicated Grade

An adverse event (AE) is defined as any untoward medical occurrence in a participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. A serious adverse event (SAE) is defined as any untoward medical occurrence that, at any dose: results in death; is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity; or is a congenital anomaly/birth defect. Medical or scientific judgment should be exercised in other situations. Adverse events were graded for severity according to the Division of AIDS (DAIDS) toxicity scales as: Grade 1 (mild), Grade 2 (moderate), Grade 3 (severe), or Grade 4 (potentially life threatening).

Time frame:
From the first dose of study medication until early withdrawal or through the Week 48 analysis data cut-off date (median of 55 study weeks)
Reported as:
Count of participants · Participants
Number of Participants With Any Adverse Event (Serious and Non-serious) of the Indicated Grade
ParticipantsDTG 50 mg BIDPlacebo BID in DB Phase; DTG 50 mg BID in Open-label Phase
Grade 104
Grade 276
Grade 323
Grade 421
SecondaryNumber of Participants With the Maximum Post-Baseline-emergent Clinical Chemistry Toxicities of the Indicated Grade

Participants with post-Baseline-emergent clinical chemistry toxicities were analyzed. Clinical chemistry toxicities were graded for severity according to the DAIDS toxicity scales as: Grade 1 (mild), Grade 2 (moderate), Grade 3 (severe), or Grade 4 (potentially life threatening).

Time frame:
From the first dose of study medication until early withdrawal or through the Week 48 analysis data cut-off date (median of 55 study weeks)
Reported as:
Count of participants · Participants
Number of Participants With the Maximum Post-Baseline-emergent Clinical Chemistry Toxicities of the Indicated Grade
ParticipantsDTG 50 mg BIDPlacebo BID in DB Phase; DTG 50 mg BID in Open-label Phase
Grade 154
Grade 255
Grade 304
Grade 401
SecondaryNumber of Participants With the Maximum Post-Baseline-emergent Hematology Toxicities of the Indicated Grade

Participants with post-Baseline-emergent hematology toxicities were analyzed. Hematology toxicities were graded for severity according to the DAIDS toxicity scales as: Grade 1 (mild), Grade 2 (moderate), Grade 3 (severe), or Grade 4 (potentially life threatening).

Time frame:
From the first dose of study medication until early withdrawal or through the Week 48 analysis data cut-off date (median of 55 study weeks)
Reported as:
Count of participants · Participants
Number of Participants With the Maximum Post-Baseline-emergent Hematology Toxicities of the Indicated Grade
ParticipantsDTG 50 mg BIDPlacebo BID in DB Phase; DTG 50 mg BID in Open-label Phase
Grade 123
Grade 225
Grade 301
Grade 400
SecondaryAUC(0-tau) of DTG

The area under the time concentration curve over the dosing interval (AUC\[0-tau\]) of DTG was assessed by a population pharmacokinetic (PK) modeling approach using pooled DTG PK data from multiple studies. Blood samples for the determination of plasma DTG concentration were collected at the following time points: pre-dose and 1-3 hours post-dose on Day 8; pre-dose and within a post-dose window (1-3 hours or 4-12 hours) on Day 28 and Week 24. For Day 8 PK, only samples collected from participants randomized to the active DTG arm were analyzed.

Time frame:
Day 8, Day 28, and Week 24
Reported as:
Geometric mean · µg*hour per mL (µg*hr/mL)
AUC(0-tau) of DTG
µg*hour per mL (µg*hr/mL)Overall Study Arm
AUC(0-tau) of DTG37.9 ± 41.8
SecondaryCmax of DTG

The maximal concentration (Cmax) of DTG was assessed by a population PK modeling approach using pooled DTG PK data from multiple studies. Blood samples for the determination of plasma DTG concentration were collected at the following time points: pre-dose and 1-3 hours post-dose on Day 8; pre-dose and within a post-dose window (1-3 hours or 4-12 hours) on Day 28 and Week 24. For Day 8 PK, only samples collected from participants randomized to the active DTG arm were analyzed.

Time frame:
Day 8, Day 28, and Week 24
Reported as:
Geometric mean · Micrograms per milliliter (µg/mL)
Cmax of DTG
Micrograms per milliliter (µg/mL)Overall Study Arm
Cmax of DTG4.14 ± 32.6
SecondaryPlasma DTG Pre-dose Concentration (C0) at Day 8, Day 28, and Week 24; and Average DTG C0 (C0 Avg) at Week 24

Blood samples for the determination of plasma DTG pre-dose concentration were collected pre-dose on Day 8, Day 28, and Week 24. For Day 8 PK, only samples collected from participants randomized to the active DTG arm were analyzed. C0 Avg was calculated at Week 24 as the mean of the concentration at Day 8, Day 28, and Week 24.

Time frame:
Day 8, Day 28, and Week 24
Reported as:
Geometric mean · µg/mL
Plasma DTG Pre-dose Concentration (C0) at Day 8, Day 28, and Week 24; and Average DTG C0 (C0 Avg) at Week 24
µg/mLDTG 50 mg BIDPlacebo BID in DB Phase; DTG 50 mg BID in Open-label Phase
Day 8 C0, n=10, 03.043 ± 44—
Day 28 C0, n=11, 161.393 ± 1892.154 ± 81
Week 24 C0, n=10, 141.864 ± 1102.201 ± 145
C0_avg, n=13, 161.820 ± 1882.307 ± 76
SecondaryNumber of Participants With the Indicated Treatment-emergent Integrase (IN) Mutations Detected at the Time of Defined Virologic Failure (PDVF), as a Measure of Genotypic Resistance

For participants meeting one of the criteria for PDVF, plasma samples collected at the time point of virologic failure were tested to evaluate any potential genotypic and/or phenotypic evolution of resistance. PDVF was defined as (A) Virologic Non-response: a decrease in plasma HIV-1 RNA of \<1 log10 copies/mL by Day 28, with subsequent confirmation, unless plasma HIV-1 RNA is \<400 copies/mL; confirmed plasma HIV-1 RNA levels \>=400 copies/mL on or after Week 24 or (B) Virologic Rebound: confirmed rebound in plasma HIV-1 RNA levels to \>=400 copies/mL after prior confirmed suppression to \<400 copies/mL; confirmed plasma HIV-1 RNA levels \>1 log10 copies/mL above the nadir value, where nadir is \>=400 copies/mL.Treatment-emergent IN mutations are those detected at the time of PDVF but not at Baseline.

Time frame:
From the first dose of study medication until early withdrawal or through the Week 48 analysis data cut-off date (median of 55 study weeks)
Reported as:
Count of participants · Participants
Number of Participants With the Indicated Treatment-emergent Integrase (IN) Mutations Detected at the Time of Defined Virologic Failure (PDVF), as a Measure of Genotypic Resistance
ParticipantsDTG 50 mg BIDPlacebo BID in DB Phase; DTG 50 mg BID in Open-label Phase
Any integrase mutation41
L74L/M10
T97A21
E138E/K10
E138K10
S147G10
N155N/H10
SecondaryNumber of Participants With the Indicated Fold Increase in Fold Change (FC) in the 50% Inhibitory Concentration Relative to Wild-type Virus for DTG (i.e. PDVF FC/Baseline FC Ratio) at the Time of PDVF, as a Measure of Phenotypic Resistance

For participants meeting one of the criteria for PDVF, plasma samples collected at the time point of virologic failure were tested to evaluate any potential genotypic and/or phenotypic evolution of resistance. The FC in IC50 (50% inhibitory concentration) for DTG relative to wild-type virus was determined for virus isolated at Baseline and at the time of PDVF. The number of participants with the indicated change (ratio) in the two values at the time of PDVF is presented. PDVF was defined as (A) Virologic Non-response: a decrease in plasma HIV-1 RNA of \<1 log10 copies/mL by Day 28, with subsequent confirmation, unless plasma HIV-1 RNA is \<400 copies/mL; confirmed plasma HIV-1 RNA levels \>=400 copies/mL on or after Week 24 or (B) Virologic Rebound: confirmed rebound in plasma HIV-1 RNA levels to \>=400 copies/mL after prior confirmed suppression to \<400 copies/mL; confirmed plasma HIV-1 RNA levels \>1 log10 copies/mL above the nadir value, where nadir is \>=400 copies/mL.

Time frame:
From the first dose of study medication until early withdrawal or through the Week 48 analysis data cut-off date (median of 55 study weeks)
Reported as:
Count of participants · Participants
Number of Participants With the Indicated Fold Increase in Fold Change (FC) in the 50% Inhibitory Concentration Relative to Wild-type Virus for DTG (i.e. PDVF FC/Baseline FC Ratio) at the Time of PDVF, as a Measure of Phenotypic Resistance
ParticipantsDTG 50 mg BIDPlacebo BID in DB Phase; DTG 50 mg BID in Open-label Phase
4-<8 fold increase in DTG FC01
>=8 fold increase in DTG FC40
SecondaryNumber of Participants Who Discontinued Study Treatment Due to AEs

The number of participants who permanently discontinued study treatment due to AEs is presented.

Time frame:
From the first dose of study medication until early withdrawal or through the Week 48 analysis data cut-off date (median of 55 study weeks)
Reported as:
Count of participants · Participants
Number of Participants Who Discontinued Study Treatment Due to AEs
ParticipantsDTG 50 mg BIDPlacebo BID in DB Phase; DTG 50 mg BID in Open-label Phase
Number of Participants Who Discontinued Study Treatment Due to AEs20
SecondaryNumber of Participants With Clinically Significant Electrocardiogram (ECG) Findings

Twelve lead ECG was performed using an automated ECG machine. The number of participants with abnormal-clinically significant ECG findings at any time on-treatment is reported.

Time frame:
Up to Week 24
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Electrocardiogram (ECG) Findings
ParticipantsDTG 50 mg BIDPlacebo BID in DB Phase; DTG 50 mg BID in Open-label Phase
Number of Participants With Clinically Significant Electrocardiogram (ECG) Findings11
SecondaryChange From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)

Vital signs including SBP and DBP were measured at Baseline, Week 24 and Week 48. Baseline was defined as the last pre-treatment value. Change from Baseline was calculated as the post-Baseline value minus the value at Baseline.

Time frame:
Baseline and Weeks 24 and 48
Reported as:
Mean · millimeters of mercury
Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)
millimeters of mercuryDTG 50 mg BIDPlacebo BID in DB Phase; DTG 50 mg BID in Open-label Phase
SBP; Baseline; n=14, 16120.4 ± 15.60113.4 ± 9.99
SBP; Week 24; n=11, 152.0 ± 12.282.8 ± 13.82
SBP; Week 48; n=6, 12-0.7 ± 19.503.1 ± 12.57
DBP; Baseline; n=14, 1678.9 ± 12.5175.1 ± 8.46
DBP; Week 24; n=11, 15-0.5 ± 9.49-1.2 ± 10.35
DBP; Week 48; n=6, 12-1.2 ± 13.92-3.2 ± 8.78
SecondaryChange From Baseline in Heart Rate

Vital signs including heart rate was measured at Baseline, Week 24 and Week 48. Baseline was defined as the last pre-treatment value. Change from Baseline was calculated as the post-Baseline value minus the value at Baseline.

Time frame:
Baseline and Weeks 24 and 48
Reported as:
Mean · beats per minute
Change From Baseline in Heart Rate
beats per minuteDTG 50 mg BIDPlacebo BID in DB Phase; DTG 50 mg BID in Open-label Phase
Baseline; n=14, 1672.5 ± 9.7075.9 ± 14.56
Week 24; n=11, 15-1.4 ± 8.420.7 ± 11.20
Week 48; 6, 122.2 ± 11.03-2.5 ± 17.76
SecondaryChange From Baseline in Albumin Level

Blood samples were collected for the analysis of clinical chemistry parameters such as albumin. Baseline was defined as the last pre-treatment value. Change from Baseline was calculated as the post-Baseline value minus the value at Baseline.

Time frame:
Baseline, Week 24 and 48
Reported as:
Mean · grams per liter
Change From Baseline in Albumin Level
grams per literDTG 50 mg BIDPlacebo BID in DB Phase; DTG 50 mg BID in Open-label Phase
Albumin; Baseline; n=14, 1643.1 ± 4.1343.4 ± 3.88
Albumin; Week 24; n=11, 150.0 ± 3.660.0 ± 3.87
Albumin; Week 48; n=8, 131.3 ± 2.55-0.8 ± 3.69
SecondaryChange From Baseline in Alkaline Phosphatase (ALP), Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST) and Creatine Kinase

Blood samples were collected for the analysis of clinical chemistry parameters such as ALP, ALT, AST and creatine kinase. Baseline was defined as the last pre-treatment value. Change from Baseline was calculated as the post-Baseline value minus the value at Baseline. NA indicates data was not available.

Time frame:
Baseline, Day 8, Day 28, Weeks 8, 12, 16, 24, 32, 40, 48, 60, 72 and 84
Reported as:
Mean · International units per liter
Change From Baseline in Alkaline Phosphatase (ALP), Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST) and Creatine Kinase
International units per literDTG 50 mg BIDPlacebo BID in DB Phase; DTG 50 mg BID in Open-label Phase
ALP; Baseline; n=14, 1691.9 ± 29.64114.9 ± 106.74
ALP; Day 8; n=13, 151.9 ± 14.01-1.2 ± 9.41
ALP; Day 28; n=13, 16-6.1 ± 10.71-0.6 ± 11.37
ALP; Week 8; n=11, 161.6 ± 15.620.6 ± 63.97
ALP; Week 12; n=12, 14-0.8 ± 10.19-0.3 ± 26.15
ALP; Week 16; n=10, 163.1 ± 12.028.2 ± 40.55
ALP; Week 24; n=11, 151.7 ± 21.723.3 ± 54.06
ALP; Week 32; n=11, 146.9 ± 19.7420.5 ± 35.89
ALP; Week 40; n=8, 122.3 ± 20.267.8 ± 24.69
ALP; Week 48; n=8, 1328.0 ± 67.5413.8 ± 32.07
ALP; Week 60; n=5, 126.0 ± 23.8612.8 ± 35.98
ALP; Week 72; n=3, 4-5.0 ± 19.2915.3 ± 10.21
ALP; Week 84; n=0, 1—22.0 ± NA
ALT; Baseline; n=14, 1624.9 ± 13.3337.4 ± 22.70
ALT; Day 8; n=13, 150.0 ± 7.02-3.8 ± 11.91
ALT; Day 28; n=13, 160.4 ± 15.45-5.3 ± 23.65
ALT; Week 8; n=11, 161.2 ± 20.30-9.2 ± 17.93
ALT; Week 12; n=12, 14-5.4 ± 4.94-8.7 ± 23.36
ALT; Week 16; n=10, 16-5.2 ± 3.97-10.1 ± 23.02
ALT; Week 24; n=11, 153.1 ± 18.66-14.5 ± 23.16
ALT; Week 32; n=11, 140.9 ± 14.01-10.6 ± 25.77
ALT; Week 40; n=8, 12-1.6 ± 8.75-7.7 ± 25.86
ALT; Week 48; n=8, 137.9 ± 20.02-9.2 ± 23.50
ALT; Week 60; n=5, 120.8 ± 7.19-8.3 ± 24.28
ALT; Week 72; n=3, 48.7 ± 17.67-29.3 ± 33.06
ALT; Week 84; n=0, 1—-3.0 ± NA
AST; Baseline; n=14, 1628.9 ± 11.1334.9 ± 14.35
AST; Day 8; n=13, 151.0 ± 11.50-2.0 ± 9.17
AST; Day 28; n=13, 16-4.0 ± 10.13-2.3 ± 17.08
AST; Week 8; n=11, 16-2.9 ± 7.57-6.3 ± 9.64
AST; Week 12; n=12, 14-4.8 ± 4.07-5.1 ± 11.78
AST; Week 16; n=10, 16-4.0 ± 2.94-6.6 ± 12.27
AST; Week 24; n=11, 151.7 ± 14.05-10.1 ± 11.87
AST; Week 32; n=11, 14-1.7 ± 6.83-7.4 ± 13.14
AST; Week 40; n=8, 12-4.9 ± 4.09-4.1 ± 12.46
AST; Week 48; n=8, 139.0 ± 27.77-5.4 ± 10.47
AST; Week 60; n=5, 12-3.2 ± 1.64-5.9 ± 9.24
AST; Week 72; n=3, 41.3 ± 8.50-13.8 ± 12.31
AST; Week 84; n=0, 1—-8.0 ± NA
Creatine Kinase; Baseline; n=14, 16162.4 ± 129.21130.3 ± 76.46
Creatine Kinase; Day 8; n=13, 15-2.1 ± 122.28-1.5 ± 53.29
Creatine Kinase; Day 28; n=13, 16-35.6 ± 96.2237.0 ± 123.10
Creatine Kinase; Week 8; n=11, 16-16.4 ± 106.99-7.3 ± 68.19
Creatine Kinase; Week 12; n=12, 14-18.8 ± 105.640.4 ± 84.85
Creatine Kinase; Week 16; n=10, 1634.2 ± 81.4480.5 ± 305.19
Creatine Kinase; Week 24; n=11, 15-24.4 ± 82.07-6.0 ± 67.29
Creatine Kinase; Week 32; n=11, 142.3 ± 54.4123.4 ± 96.88
Creatine Kinase; Week 40; n=8, 12-50.0 ± 93.4566.3 ± 168.54
Creatine Kinase; Week 48; n=8, 137.8 ± 71.5716.1 ± 68.96
Creatine Kinase; Week 60; n=5, 12-12.2 ± 23.3018.8 ± 86.19
Creatine Kinase; Week 72; n=3, 435.0 ± 68.61-29.0 ± 76.27
Creatine Kinase; Week 84; n=0, 1—-134.0 ± NA
SecondaryChange From Baseline in Total Bilirubin (T. Bil) and Creatinine Levels

Blood samples were collected for the analysis of clinical chemistry parameters such as T. Bil and creatinine. Baseline was defined as the last pre-treatment value. Change from Baseline was calculated as the post-Baseline value minus the value at Baseline. NA indicates data was not available.

Time frame:
Baseline, Day 8, Day 28, Weeks 8, 12, 16, 24, 32, 40, 48, 60, 72 and 84
Reported as:
Mean · Micromoles per liter
Change From Baseline in Total Bilirubin (T. Bil) and Creatinine Levels
Micromoles per literDTG 50 mg BIDPlacebo BID in DB Phase; DTG 50 mg BID in Open-label Phase
T. Bil.; Baseline; n=14, 1610.0 ± 4.517.5 ± 3.14
T. Bil.; Day 8; n=13, 150.8 ± 6.81-1.1 ± 2.12
T. Bil.; Day 28; n=13, 16-0.2 ± 6.192.1 ± 9.78
T. Bil.; Week 8; n=11, 160.0 ± 4.203.1 ± 13.76
T. Bil.; Week 12; n=12, 140.5 ± 4.76-0.6 ± 2.14
T. Bil.; Week 16; n=10, 160.6 ± 3.891.9 ± 10.89
T. Bil.; Week 24; n=11, 150.2 ± 2.892.1 ± 8.19
T. Bil.; Week 32; n=11, 14-0.4 ± 3.202.3 ± 10.16
T. Bil.; Week 40; n=8, 120.0 ± 3.703.3 ± 12.43
T. Bil.; Week 48; n=8, 13-0.8 ± 4.133.2 ± 12.18
T. Bil.; Week 60; n=5, 12-2.4 ± 2.612.3 ± 11.63
T. Bil.; Week 72; n=3, 4-1.3 ± 4.169.5 ± 16.36
T. Bil.; Week 84; n=0, 1—2.0 ± NA
Creatinine; Baseline; n=14, 1686.94 ± 18.97188.96 ± 24.013
Creatinine; Day 8; n=13, 1510.96 ± 24.5050.11 ± 14.873
Creatinine; Day 28; n=13, 1612.72 ± 19.69713.58 ± 21.030
Creatinine; Week 8; n=11, 1612.15 ± 8.57015.79 ± 19.574
Creatinine; Week 12; n=12, 146.86 ± 9.1539.85 ± 13.274
Creatinine; Week 16; n=10, 168.22 ± 13.4647.68 ± 13.031
Creatinine; Week 24; n=11, 151.63 ± 11.09813.31 ± 17.347
Creatinine; Week 32; n=11, 140.98 ± 7.44115.96 ± 11.902
Creatinine; Week 40; n=8, 123.58 ± 10.78812.94 ± 13.870
Creatinine; Week 48; n=8, 134.21 ± 19.45012.85 ± 9.128
Creatinine; Week 60; n=5, 124.96 ± 5.56011.72 ± 15.820
Creatinine; Week 72; n=3, 40.93 ± 8.52913.25 ± 16.957
Creatinine; Week 84; n=0, 1—1.80 ± NA
SecondaryChange From Baseline in Cholesterol, Chloride, Carbon Dioxide (CO2)/Bicarbonate (HCO3), Glucose, High Density Lipoprotein Cholesterol, Potassium, Low Density Lipoprotein (LDL) Cholesterol, Sodium, Phosphorus, Triglycerides and Urea/Blood Urea Nitrogen

Blood samples were collected for the analysis of clinical chemistry parameters such as cholesterol, chloride, CO2/HCO3, glucose, high density lipoprotein (HDL) cholesterol, potassium, LDL cholesterol, sodium, phosphorus inorganic, triglycerides and urea/blood urea nitrogen (BUN). Baseline was defined as the last pre-treatment value. Change from Baseline was calculated as the post-Baseline value minus the value at Baseline. NA indicates data was not available.

Time frame:
Baseline, Day 8, Day 28, Weeks 8, 12, 16, 24, 32, 40, 48, 60, 72 and 84
Reported as:
Mean · Millimoles per liter
Change From Baseline in Cholesterol, Chloride, Carbon Dioxide (CO2)/Bicarbonate (HCO3), Glucose, High Density Lipoprotein Cholesterol, Potassium, Low Density Lipoprotein (LDL) Cholesterol, Sodium, Phosphorus, Triglycerides and Urea/Blood Urea Nitrogen
Millimoles per literDTG 50 mg BIDPlacebo BID in DB Phase; DTG 50 mg BID in Open-label Phase
Cholesterol; Baseline; n=8, 103.819 ± 0.92194.725 ± 1.7430
Cholesterol; Week 12; n=6, 80.433 ± 0.46220.538 ± 0.9598
Cholesterol; Week 24; n=6, 100.308 ± 0.31370.585 ± 1.0296
Cholesterol; Week 48; n=3, 70.567 ± 0.20210.421 ± 1.2770
Cholesterol; Week 60; n=2, 50.375 ± 0.9546-0.020 ± 1.3326
Cholesterol; Week 72; n=0, 1—1.350 ± NA
Chloride; Baseline; n=14, 16104.1 ± 1.59105.4 ± 3.32
Chloride; Day 8; n=13, 150.5 ± 1.610.4 ± 2.03
Chloride; Day 28; n=13, 160.4 ± 2.26-0.5 ± 2.58
Chloride; Week 8; n=11, 160.5 ± 1.97-1.8 ± 3.08
Chloride; Week 12; n=12, 14-0.8 ± 1.710.1 ± 2.73
Chloride; Week 16; n=10, 161.4 ± 1.90-1.0 ± 2.73
Chloride; Week 24; n=11, 150.9 ± 1.45-1.2 ± 3.14
Chloride; Week 32; n=11, 141.1 ± 2.210.0 ± 2.57
Chloride; Week 40; n=8, 120.5 ± 2.511.3 ± 2.80
Chloride; Week 48; n=8, 131.5 ± 3.74-0.1 ± 3.38
Chloride; Week 60; n=5, 122.0 ± 2.121.1 ± 2.81
Chloride; Week 72; n=3, 42.0 ± 2.651.0 ± 2.94
Chloride; Week 84; n=0, 1—-2.0 ± NA
CO2/HCO3; Baseline; n=14, 1622.5 ± 2.0720.8 ± 4.12
CO2/HCO3; Day 8; n=13, 150.2 ± 1.300.1 ± 2.25
CO2/HCO3; Day 28; n=13, 160.4 ± 2.291.1 ± 2.47
CO2/HCO3; Week 8; n=11, 161.2 ± 1.661.6 ± 3.40
CO2/HCO3; Week 12; n=12, 141.7 ± 1.921.9 ± 2.73
CO2/HCO3; Week 16; n=10, 16-0.2 ± 2.391.8 ± 3.42
CO2/HCO3; Week 24; n=11, 150.9 ± 1.921.5 ± 2.92
CO2/HCO3; Week 32; n=11, 141.5 ± 2.210.8 ± 2.69
CO2/HCO3; Week 40; n=8, 120.9 ± 2.30-0.2 ± 2.25
CO2/HCO3; Week 48; n=8, 13-0.4 ± 2.131.7 ± 3.01
CO2/HCO3; Week 60; n=5, 120.8 ± 1.300.3 ± 2.42
CO2/HCO3; Week 72; n=3, 42.0 ± 3.61-0.3 ± 1.89
CO2/HCO3; Week 84; n=0, 1—4.0 ± NA
Glucose; Baseline; n=12, 164.84 ± 0.5355.56 ± 1.994
Glucose; Week 12; n=11, 14-0.01 ± 0.6770.04 ± 0.679
Glucose; Week 24; n=10, 150.17 ± 0.957-0.08 ± 1.024
Glucose; Week 48; n=7, 130.13 ± 0.4390.40 ± 1.143
Glucose; Week 60; n=3, 120.20 ± 0.300-0.18 ± 0.723
Glucose; Week 72; n=2, 40.45 ± 0.0710.20 ± 0.744
HDL Cholesterol; Baseline; n=8, 100.956 ± 0.27181.090 ± 0.2846
HDL Cholesterol; Week 12; n=6, 80.117 ± 0.06830.156 ± 0.2485
HDL Cholesterol; Week 24; n=6, 100.025 ± 0.18640.130 ± 0.2573
HDL Cholesterol; Week 48; n=3, 70.117 ± 0.11550.136 ± 0.3363
HDL Cholesterol; Week 60; n=2, 5-0.025 ± 0.03540.010 ± 0.3896
HDL Cholesterol; Week 72; n=0, 1—0.350 ± NA
Potassium; Baseline; n=14, 164.16 ± 0.4204.13 ± 0.377
Potassium; Day 8; n=13, 15-0.09 ± 0.198-0.01 ± 0.301
Potassium; Day 28; n=13, 160.19 ± 0.4390.14 ± 0.518
Potassium; Week 8; n=11, 160.12 ± 0.3790.19 ± 0.421
Potassium; Week 12; n=12, 140.03 ± 0.2530.06 ± 0.373
Potassium; Week 16; n=10, 16-0.06 ± 0.360-0.08 ± 0.556
Potassium; Week 24; n=11, 150.17 ± 0.3740.27 ± 0.641
Potassium; Week 32; n=11, 14-0.04 ± 0.3290.27 ± 0.327
Potassium; Week 40; n=8, 12-0.01 ± 0.1890.12 ± 0.259
Potassium; Week 48; n=8, 130.15 ± 0.5320.28 ± 0.508
Potassium; Week 60; n=5, 120.06 ± 0.2880.03 ± 0.614
Potassium; Week 72; n=3, 40.37 ± 0.2080.02 ± 0.512
Potassium; Week 84; n=0, 1—0.20 ± NA
LDL Cholesterol; Baseline; n=8, 92.218 ± 0.91342.591 ± 1.3696
LDL Cholesterol; Week 12; n=6, 80.293 ± 0.41970.500 ± 0.5145
LDL Cholesterol; Week 24; n=6, 90.032 ± 0.58540.596 ± 0.7389
LDL Cholesterol; Week 48; n=3, 60.330 ± 0.04580.322 ± 0.7725
LDL Cholesterol; Week 60; n=2, 40.125 ± 0.5303-0.008 ± 1.0682
LDL Cholesterol; Week 72; n=0, 1—1.110 ± NA
Sodium; Baseline; n=14, 16138.8 ± 2.26138.5 ± 2.22
Sodium; Day 8; n=13, 150.2 ± 1.64-0.1 ± 2.02
Sodium; Day 28; n=13, 16-0.2 ± 3.11-0.4 ± 2.60
Sodium; Week 8; n=11, 160.2 ± 2.14-0.4 ± 2.03
Sodium; Week 12; n=12, 14-0.5 ± 1.880.4 ± 2.53
Sodium; Week 16; n=10, 161.3 ± 2.060.2 ± 1.94
Sodium; Week 24; n=11, 150.5 ± 1.51-0.1 ± 2.33
Sodium; Week 32; n=11, 140.8 ± 1.600.1 ± 1.41
Sodium; Week 40; n=8, 121.0 ± 2.140.5 ± 1.57
Sodium; Week 48; n=8, 130.9 ± 3.560.9 ± 2.40
Sodium; Week 60; n=5, 122.4 ± 1.950.7 ± 2.46
Sodium; Week 72; n=3, 41.3 ± 2.520.3 ± 1.50
Sodium; Week 84; n=0, 1—0.0 ± NA
Phosphorus, inorganic; Baseline; n=14, 161.018 ± 0.15521.128 ± 0.1390
Phosphorus, inorganic; Day 8; n=13, 150.012 ± 0.1261-0.123 ± 0.1635
Phosphorus, inorganic; Day 28; n=13, 160.065 ± 0.2357-0.075 ± 0.1713
Phosphorus, inorganic; Week 8; n=11, 160.018 ± 0.1722-0.075 ± 0.2244
Phosphorus, inorganic; Week 12; n=12, 140.033 ± 0.1542-0.054 ± 0.1322
Phosphorus, inorganic; Week 16; n=10, 160.080 ± 0.2263-0.053 ± 0.2617
Phosphorus, inorganic; Week 24; n=11, 15-0.050 ± 0.1204-0.023 ± 0.1954
Phosphorus, inorganic; Week 32; n=11, 14-0.036 ± 0.1343-0.050 ± 0.1787
Phosphorus, inorganic; Week 40; n=8, 120.000 ± 0.1035-0.046 ± 0.2340
Phosphorus, inorganic; Week 48; n=8, 130.025 ± 0.1282-0.031 ± 0.1331
Phosphorus, inorganic; Week 60; n=5, 120.020 ± 0.1304-0.042 ± 0.1311
Phosphorus, inorganic; Week 72; n=3, 40.017 ± 0.12580.013 ± 0.1031
Phosphorus, inorganic; Week 84; n=0, 1—0.100 ± NA
Triglycerides; Baseline; n=8, 101.410 ± 0.50052.336 ± 1.1103
Triglycerides; Week 12; n=6, 80.047 ± 0.6380-0.260 ± 1.1159
Triglycerides; Week 24; n=6, 100.547 ± 0.9273-0.458 ± 1.2066
Triglycerides; Week 48; n=3, 70.260 ± 0.3894-0.486 ± 1.3993
Triglycerides; Week 60; n=2, 50.590 ± 0.8344-0.580 ± 1.0562
Triglycerides; Week 72; n=0, 1—-0.240 ± NA
Urea/BUN; Baseline; n=14, 165.64 ± 1.1675.72 ± 2.324
Urea/BUN; Day 8; n=13, 150.04 ± 1.233-0.43 ± 1.252
Urea/BUN; Day 28; n=13, 16-0.23 ± 1.678-0.13 ± 1.875
Urea/BUN; Week 8; n=11, 16-0.09 ± 1.200-0.59 ± 1.985
Urea/BUN; Week 12; n=12, 140.25 ± 1.270-0.50 ± 1.676
Urea/BUN; Week 16; n=10, 16-0.05 ± 1.787-1.00 ± 1.304
Urea/BUN; Week 24; n=11, 15-0.09 ± 1.200-0.27 ± 1.841
Urea/BUN; Week 32; n=11, 14-0.55 ± 1.1500.57 ± 1.708
Urea/BUN; Week 40; n=8, 12-0.19 ± 1.3870.29 ± 1.339
Urea/BUN; Week 48; n=8, 130.38 ± 1.1570.88 ± 1.927
Urea/BUN; Week 60; n=5, 120.30 ± 0.9080.54 ± 1.888
Urea/BUN; Week 72; n=3, 40.50 ± 0.5000.50 ± 0.408
Urea/BUN; Week 84; n=0, 1—0.00 ± NA
SecondaryChange From Baseline in Creatinine Clearance

Creatinine clearance was calculated using Cockcroft-Gault formula. Baseline was defined as the last pre-treatment value. Change from Baseline was calculated as the post-Baseline value minus the value at Baseline.

Time frame:
Baseline, Day 8, Day 28, Week 8, Week 16, Week 24, Week 32 and Week 48
Reported as:
Mean · Milliliters per minute
Change From Baseline in Creatinine Clearance
Milliliters per minuteDTG 50 mg BIDPlacebo BID in DB Phase; DTG 50 mg BID in Open-label Phase
Baseline; n=14, 16106.8 ± 31.79104.8 ± 36.96
Day 8; n=1, 0-13.0 ± NA—
Day 28; n=13, 16-10.5 ± 13.06-10.4 ± 13.06
Week 8; n=0, 1—-12.0 ± NA
Week 16; n=10, 15-7.3 ± 12.00-12.5 ± 16.41
Week 24; n=11, 15-2.3 ± 13.94-13.9 ± 17.38
Week 32; n=9, 14-1.4 ± 8.82-16.0 ± 16.31
Week 48; n=6, 12-6.8 ± 17.61-16.5 ± 14.34
SecondaryChange From Baseline in Lipase Levels

Blood samples were collected for the analysis of clinical chemistry parameters such as lipase level. Baseline was defined as the last pre-treatment value. Change from Baseline was calculated as the post-Baseline value minus the value at Baseline. NA indicates data was not available.

Time frame:
Baseline, Day 8, Day 28, Weeks 8, 12, 16, 24, 32, 40, 48, 60, 72 and 84
Reported as:
Mean · Units per liter
Change From Baseline in Lipase Levels
Units per literDTG 50 mg BIDPlacebo BID in DB Phase; DTG 50 mg BID in Open-label Phase
Lipase; Baseline; n=14, 1629.1 ± 12.3734.0 ± 18.54
Lipase; Day 8; n=14, 153.4 ± 9.1912.5 ± 32.97
Lipase; Day 28; n=13, 163.3 ± 9.1817.7 ± 63.64
Lipase; Week 8; n=11, 162.6 ± 8.6513.6 ± 42.89
Lipase; Week 12; n=11, 14-2.4 ± 8.913.0 ± 19.24
Lipase; Week 16; n=10, 167.6 ± 13.94-0.8 ± 12.90
Lipase; Week 24; n=11, 15-2.7 ± 9.9110.5 ± 29.18
Lipase; Week 32; n=11, 140.8 ± 9.8220.6 ± 49.70
Lipase; Week 40; n=8, 120.6 ± 8.535.6 ± 19.78
Lipase; Week 48; n=8, 133.8 ± 6.183.4 ± 16.05
Lipase; Week 60; n=5, 125.0 ± 8.405.9 ± 22.01
Lipase; Week 72; n=3, 416.0 ± 14.1141.0 ± 94.20
Lipase; Week 84; n=0, 1—-9.0 ± NA
SecondaryChange From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Total Neutrophils, Platelet and White Blood Cell (WBC) Count

Blood samples were collected for the analysis of hematology parameters such as basophils, eosinophils. Baseline was defined as the last pre-treatment value. Change from Baseline was calculated as the post-Baseline value minus the value at Baseline. NA indicates data was not available.

Time frame:
Baseline, Day 8, Day 28, Weeks 8, 12, 16, 24, 32, 40, 48, 60, 72 and 84
Reported as:
Mean · Giga cells per liter
Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Total Neutrophils, Platelet and White Blood Cell (WBC) Count
Giga cells per literDTG 50 mg BIDPlacebo BID in DB Phase; DTG 50 mg BID in Open-label Phase
Basophils; Baseline; n=14, 160.016 ± 0.01220.015 ± 0.0126
Basophils; Day 8; n=14, 150.006 ± 0.01340.002 ± 0.0094
Basophils; Day 28; n=13, 160.005 ± 0.01760.004 ± 0.0222
Basophils; Week 8; n=11, 16-0.001 ± 0.01220.004 ± 0.0120
Basophils; Week 12; n=12, 14-0.001 ± 0.01440.000 ± 0.0124
Basophils; Week 16; n=12, 16-0.002 ± 0.01470.005 ± 0.0137
Basophils; Week 24; n=11, 150.001 ± 0.01580.007 ± 0.0188
Basophils; Week 32; n=11, 130.002 ± 0.01080.005 ± 0.0185
Basophils; Week 40; n=8, 12-0.000 ± 0.02070.003 ± 0.0144
Basophils; Week 48; n=8, 130.006 ± 0.01300.008 ± 0.0174
Basophils; Week 60; n=5, 12-0.002 ± 0.01640.004 ± 0.0173
Basophils; Week 72; n=3, 4-0.003 ± 0.01530.008 ± 0.0275
Basophils; Week 84; n=0, 1—0.010 ± NA
Eosinophils; Baseline; n=14, 160.087 ± 0.09350.158 ± 0.1681
Eosinophils; Day 8; n=14, 150.016 ± 0.03880.005 ± 0.1076
Eosinophils; Day 28; n=13, 160.023 ± 0.02530.033 ± 0.1939
Eosinophils; Week 8; n=11, 160.041 ± 0.05610.090 ± 0.1464
Eosinophils; Week 12; n=12, 140.023 ± 0.04920.240 ± 0.4390
Eosinophils; Week 16; n=12, 160.024 ± 0.08870.141 ± 0.3009
Eosinophils; Week 24; n=11, 15-0.003 ± 0.09870.159 ± 0.3737
Eosinophils; Week 32; n=11, 130.016 ± 0.11080.075 ± 0.1921
Eosinophils; Week 40; n=8, 12-0.015 ± 0.12850.011 ± 0.1054
Eosinophils; Week 48; n=8, 13-0.028 ± 0.12410.122 ± 0.2186
Eosinophils; Week 60; n=5, 12-0.038 ± 0.13920.098 ± 0.2143
Eosinophils; Week 72; n=3, 4-0.043 ± 0.11850.053 ± 0.0660
Eosinophils; Week 84; n=0, 1—0.240 ± NA
Lymphocytes; Baseline; n=14, 161.656 ± 0.90391.418 ± 0.7921
Lymphocytes; Day 8; n=14, 150.165 ± 0.49100.040 ± 0.3262
Lymphocytes; Day 28; n=13, 160.132 ± 0.48410.297 ± 0.3042
Lymphocytes; Week 8; n=11, 160.490 ± 0.55910.536 ± 0.6238
Lymphocytes; Week 12; n=12, 140.417 ± 0.94010.525 ± 0.4922
Lymphocytes; Week 16; n=12, 160.554 ± 0.64020.594 ± 0.7014
Lymphocytes; Week 24; n=11, 150.271 ± 0.74660.647 ± 0.8692
Lymphocytes; Week 32; n=11, 130.173 ± 0.71660.818 ± 0.6910
Lymphocytes; Week 40; n=8, 120.169 ± 0.66000.519 ± 0.6709
Lymphocytes; Week 48; n=8, 130.474 ± 0.42070.563 ± 0.5703
Lymphocytes; Week 60; n=5, 120.526 ± 0.35780.663 ± 0.6135
Lymphocytes; Week 72; n=3, 40.673 ± 0.53270.623 ± 0.4280
Lymphocytes; Week 84; n=0, 1—0.640 ± NA
Monocytes; Baseline; n=14, 160.367 ± 0.20750.306 ± 0.1117
Monocytes; Day 8; n=14, 150.003 ± 0.23790.027 ± 0.1460
Monocytes; Day 28; n=13, 16-0.042 ± 0.19990.031 ± 0.1196
Monocytes; Week 8; n=11, 16-0.022 ± 0.12560.037 ± 0.1111
Monocytes; Week 12; n=12, 14-0.053 ± 0.12150.065 ± 0.1075
Monocytes; Week 16; n=12, 16-0.027 ± 0.12620.089 ± 0.1430
Monocytes; Week 24; n=11, 15-0.067 ± 0.11520.017 ± 0.1716
Monocytes; Week 32; n=11, 13-0.059 ± 0.12080.017 ± 0.1616
Monocytes; Week 40; n=8, 12-0.030 ± 0.06850.011 ± 0.0983
Monocytes; Week 48; n=8, 13-0.050 ± 0.15980.018 ± 0.0985
Monocytes; Week 60; n=5, 12-0.088 ± 0.1359-0.003 ± 0.1305
Monocytes; Week 72; n=3, 40.003 ± 0.09870.055 ± 0.1196
Monocytes; Week 84; n=0, 1—-0.230 ± NA
Total neutrophils; Baseline; n=14, 162.327 ± 1.20681.869 ± 1.0565
Total neutrophils; Day 8; n=14, 150.090 ± 0.90290.072 ± 0.6338
Total neutrophils; Day 28; n=13, 160.196 ± 0.70170.659 ± 0.9376
Total neutrophils; Week 8; n=11, 160.480 ± 0.79190.344 ± 0.7325
Total neutrophils; Week 12; n=12, 140.022 ± 0.59460.357 ± 0.5410
Total neutrophils; Week 16; n=12, 160.780 ± 1.71871.030 ± 0.7759
Total neutrophils; Week 24; n=11, 15-0.128 ± 0.78510.746 ± 1.3053
Total neutrophils; Week 32; n=11, 130.213 ± 0.95250.875 ± 1.0945
Total neutrophils; Week 40; n=8, 120.224 ± 1.02740.390 ± 0.4501
Total neutrophils; Week 48; n=8, 130.144 ± 0.58070.986 ± 1.0983
Total neutrophils; Week 60; n=5, 120.162 ± 0.79591.507 ± 1.7191
Total neutrophils; Week 72; n=3, 40.783 ± 1.61012.363 ± 2.0072
Total neutrophils; Week 84; n=0, 1—2.060 ± NA
Platelet; Baseline; n=14, 16173.0 ± 65.30176.9 ± 56.97
Platelet; Day 8; n=14, 1521.6 ± 29.2316.5 ± 29.08
Platelet; Day 28; n=13, 1633.9 ± 29.8730.8 ± 43.76
Platelet; Week 8; n=11, 1657.8 ± 70.8629.1 ± 57.51
Platelet; Week 12; n=12, 1436.5 ± 33.6839.2 ± 56.51
Platelet; Week 16; n=12, 1635.7 ± 39.5852.6 ± 56.43
Platelet; Week 24; n=11, 1533.5 ± 31.4158.7 ± 64.10
Platelet; Week 32; n=11, 1312.1 ± 33.8755.6 ± 74.60
Platelet; Week 40; n=8, 1225.6 ± 38.3844.9 ± 48.17
Platelet; Week 48; n=8, 1324.6 ± 36.4953.5 ± 63.73
Platelet; Week 60; n=5, 1243.0 ± 18.3651.5 ± 58.12
Platelet; Week 72; n=3, 434.3 ± 40.1564.0 ± 94.89
Platelet; Week 84; n=0, 1—88.0 ± NA
WBC; Baseline; n=14, 164.44 ± 1.7523.78 ± 1.522
WBC; Day 8; n=14, 150.29 ± 1.0820.15 ± 0.890
WBC; Day 28; n=13, 160.33 ± 0.9461.03 ± 1.105
WBC; Week 8; n=11, 161.00 ± 1.0151.02 ± 1.008
WBC; Week 12; n=12, 140.42 ± 1.1921.19 ± 1.005
WBC; Week 16; n=12, 161.36 ± 2.0501.86 ± 1.398
WBC; Week 24; n=11, 150.09 ± 1.2761.59 ± 2.075
WBC; Week 32; n=11, 130.35 ± 1.2641.78 ± 1.600
WBC; Week 40; n=8, 120.36 ± 1.1620.93 ± 0.965
WBC; Week 48; n=8, 130.56 ± 0.6551.70 ± 1.480
WBC; Week 60; n=5, 120.58 ± 0.9732.25 ± 1.579
WBC; Week 72; n=3, 41.43 ± 1.2103.10 ± 2.349
WBC; Week 84; n=0, 1—2.70 ± NA
SecondaryChange From Baseline in Hemoglobin Level

Blood samples were collected for the analysis of hematology parameters such as hemoglobin. Baseline was defined as the last pre-treatment value. Change from Baseline was calculated as the post-Baseline value minus the value at Baseline. NA indicates data was not available.

Time frame:
Baseline, Day 8, Day 28, Weeks 8, 12, 16, 24, 32, 40, 48, 60, 72 and 84
Reported as:
Mean · Grams per liter
Change From Baseline in Hemoglobin Level
Grams per literDTG 50 mg BIDPlacebo BID in DB Phase; DTG 50 mg BID in Open-label Phase
Baseline; n=14, 16132.9 ± 16.16129.9 ± 21.08
Day 8; n=14, 15-1.0 ± 6.98-1.3 ± 4.37
Day 28; n=13, 16-2.5 ± 8.76-0.9 ± 9.62
Week 8; n=11, 16-4.5 ± 13.712.6 ± 12.48
Week 12; n=12, 14-1.0 ± 12.592.1 ± 11.02
Week 16; n=12 160.0 ± 15.471.9 ± 10.14
Week 24; n=11, 15-0.6 ± 10.601.5 ± 8.82
Week 32; n=11, 13-2.4 ± 10.661.5 ± 9.49
Week 40; n=8, 12-0.9 ± 12.140.7 ± 11.32
Week 48; n=8, 130.0 ± 9.800.5 ± 13.48
Week 60; n=5, 12-1.8 ± 13.995.0 ± 13.22
Week 72; n=3, 4-4.3 ± 7.377.0 ± 8.72
Week 84; n=0, 1—-6.0 ± NA
SecondaryChange From Baseline in Hematocrit Level

Blood samples were collected for the analysis of hematology parameters such as hematocrit level. Baseline was defined as the last pre-treatment value. Change from Baseline was calculated as the post-Baseline value minus the value at Baseline. NA indicates data was not available.

Time frame:
Baseline, Day 8, Day 28, Weeks 8, 12, 16, 24, 32, 40, 48, 60, 72 and 84
Reported as:
Mean · Proportion of red blood cells in blood
Change From Baseline in Hematocrit Level
Proportion of red blood cells in bloodDTG 50 mg BIDPlacebo BID in DB Phase; DTG 50 mg BID in Open-label Phase
Baseline; n=14, 160.4024 ± 0.052590.3974 ± 0.06496
Day 8; n=14, 15-0.0015 ± 0.02666-0.0049 ± 0.01515
Day 28; n=13, 16-0.0066 ± 0.03105-0.0043 ± 0.03313
Week 8; n=11, 16-0.0105 ± 0.043830.0092 ± 0.04092
Week 12; n=12, 14-0.0027 ± 0.037020.0054 ± 0.03419
Week 16; n=12, 16-0.0033 ± 0.042750.0021 ± 0.03054
Week 24; n=11, 15-0.0025 ± 0.037070.0062 ± 0.02787
Week 32; n=11, 13-0.0081 ± 0.033100.0062 ± 0.03144
Week 40; n=8, 12-0.0005 ± 0.032570.0063 ± 0.03601
Week 48; n=8, 130.0065 ± 0.029190.0078 ± 0.04331
Week 60; n=5, 12-0.0024 ± 0.040000.0200 ± 0.04520
Week 72; n=3, 4-0.0170 ± 0.031190.0248 ± 0.02943
Week 84; n=0, 1—-0.0090 ± NA
SecondaryChange From Baseline in Mean Corpuscle Volume

Blood samples were collected for the analysis of hematology parameters such as mean corpuscle volume. Baseline was defined as the last pre-treatment value. Change from Baseline was calculated as the post-Baseline value minus the value at Baseline. NA indicates data was not available.

Time frame:
Baseline, Day 8, Day 28, Weeks 8, 12, 16, 24, 32, 40, 48, 60, 72 and 84
Reported as:
Mean · Femtoliter
Change From Baseline in Mean Corpuscle Volume
FemtoliterDTG 50 mg BIDPlacebo BID in DB Phase; DTG 50 mg BID in Open-label Phase
Baseline; n=14, 1699.1 ± 8.8397.8 ± 9.28
Day 8; n=14, 150.1 ± 2.350.3 ± 1.71
Day 28; n=13, 161.2 ± 3.260.3 ± 3.82
Week 8; n=11, 160.3 ± 3.77-0.3 ± 6.02
Week 12; n=12, 141.1 ± 7.73-1.5 ± 7.39
Week 16; n=12, 160.3 ± 7.84-2.2 ± 8.85
Week 24; n=11, 15-0.3 ± 8.25-2.0 ± 10.36
Week 32; n=11, 13-1.0 ± 8.54-2.4 ± 10.87
Week 40; n=8, 122.5 ± 8.75-0.7 ± 11.41
Week 48; n=8, 132.0 ± 7.76-1.0 ± 11.73
Week 60; n=5, 121.4 ± 7.89-1.2 ± 11.82
Week 72; n=3, 40.3 ± 10.122.3 ± 14.10
Week 84; n=0, 1—18.0 ± NA
SecondaryChange From Baseline in Red Blood Cell Count

Blood samples were collected for the analysis of hematology parameters such as RBC. Baseline was defined as the last pre-treatment value. Change from Baseline was calculated as the post-Baseline value minus the value at Baseline. NA indicates data was not available.

Time frame:
Baseline, Day 8, Day 28, Weeks 8, 12, 16, 24, 32, 40, 48, 60, 72 and 84
Reported as:
Mean · Trillion cells per liter
Change From Baseline in Red Blood Cell Count
Trillion cells per literDTG 50 mg BIDPlacebo BID in DB Phase; DTG 50 mg BID in Open-label Phase
Baseline; n=14, 164.09 ± 0.5504.09 ± 0.731
Day 8; n=14, 150.00 ± 0.254-0.04 ± 0.140
Day 28; n=13, 16-0.08 ± 0.309-0.06 ± 0.318
Week 8; n=11, 16-0.14 ± 0.4340.12 ± 0.435
Week 12; n=12, 14-0.05 ± 0.4930.15 ± 0.477
Week 16; n=12, 16-0.03 ± 0.5290.13 ± 0.478
Week 24; n=11, 150.02 ± 0.4640.18 ± 0.514
Week 32; n=11, 13-0.04 ± 0.4670.18 ± 0.504
Week 40; n=8, 12-0.08 ± 0.3920.09 ± 0.658
Week 48; n=8, 13-0.00 ± 0.3340.15 ± 0.625
Week 60; n=5, 12-0.06 ± 0.4280.28 ± 0.625
Week 72; n=3, 4-0.20 ± 0.1730.25 ± 0.759
Week 84; n=0, 1—-0.60 ± NA

Adverse events

Collected over Serious adverse events (SAEs) and non-serious AEs were collected in the time period from the first dose of study medication until early withdrawal or through the Week 48 analysis data cut-off date (median of 55 study weeks).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
DTG 50mg BID2/14 (14.3%)5/14 (35.7%)11/14 (78.6%)
Placebo BID in DB Phase; DTG 50 mg BID in Open-label Phase0/16 (0%)4/16 (25%)14/16 (87.5%)
Most frequent serious events
Showing 10 of 16
Most frequent serious events
EventDTG 50mg BIDPlacebo BID in DB Phase; DTG 50 mg BID in Open-label Phase
Coronary artery diseaseCardiac disorders1/140/16
DiarrhoeaGastrointestinal disorders1/140/16
Cardiac deathGeneral disorders1/140/16
Renal failure acuteRenal and urinary disorders1/140/16
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders1/140/16
Cardiac arrestCardiac disorders1/140/16
Chest painGeneral disorders1/140/16
PneumoniaInfections and infestations1/140/16
Multiple fracturesInjury, poisoning and procedural complications0/141/16
Road traffic accidentInjury, poisoning and procedural complications0/141/16
Most frequent other events
Showing 10 of 87
Most frequent other events
EventDTG 50mg BIDPlacebo BID in DB Phase; DTG 50 mg BID in Open-label Phase
DiarrhoeaGastrointestinal disorders3/142/16
HeadacheNervous system disorders3/141/16
NauseaGastrointestinal disorders3/142/16
LymphadenopathyBlood and lymphatic system disorders3/140/16
Upper respiratory tract infectionInfections and infestations1/143/16
DepressionPsychiatric disorders1/143/16
Abdominal pain upperGastrointestinal disorders2/140/16
DizzinessNervous system disorders2/140/16
AsthmaRespiratory, thoracic and mediastinal disorders2/141/16
Chest painGeneral disorders2/140/16

Baseline characteristics

Age, Continuous
Age, Continuous(Years)DTG 50 mg BIDPlacebo BID in DB Phase; DTG 50 mg BID in Open-label PhaseTotal
Mean47.5 ± 11.5648.6 ± 8.8548.1 ± 10.04
Sex: Female, Male
Sex: Female, Male(Participants)DTG 50 mg BIDPlacebo BID in DB Phase; DTG 50 mg BID in Open-label PhaseTotal
Female246
Male121224
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)DTG 50 mg BIDPlacebo BID in DB Phase; DTG 50 mg BID in Open-label PhaseTotal
African American/African Heritage8816
American Indian or Alaska Native011
White - Arabic/North African Heritage101
White - White/Caucasian/European Heritage4711
Missing: None of the Available Races Applied101
08

Study locations

25 sites
  • GSK Investigational Site
    Little Rock, Arkansas 72207, United States
  • GSK Investigational Site
    Bakersfield, California 93301, United States
  • GSK Investigational Site
    Beverly Hills, California 90211, United States
  • GSK Investigational Site
    Los Angeles, California 90069, United States
  • GSK Investigational Site
    San Diego, California 92103-8208, United States
  • GSK Investigational Site
    Norwalk, Connecticut 06850, United States
  • GSK Investigational Site
    Washington, District of Columbia 20007, United States
  • GSK Investigational Site
    Washington, District of Columbia 20009, United States
  • GSK Investigational Site
    Fort Lauderdale, Florida 33316, United States
  • GSK Investigational Site
    Fort Pierce, Florida 34982, United States
  • GSK Investigational Site
    Orlando, Florida 32803, United States
  • GSK Investigational Site
    Augusta, Georgia 30912, United States
  • GSK Investigational Site
    Savannah, Georgia 31401, United States
  • GSK Investigational Site
    Maywood, Illinois 60153, United States
  • GSK Investigational Site
    Boston, Massachusetts 02115, United States
  • GSK Investigational Site
    Hillsborough, New Jersey 08844, United States
  • GSK Investigational Site
    Bronx, New York 10467, United States
  • GSK Investigational Site
    Buffalo, New York 14215, United States
  • GSK Investigational Site
    New York, New York 10011, United States
  • GSK Investigational Site
    Valhalla, New York 10595, United States
  • GSK Investigational Site
    Durham, North Carolina 27710, United States
  • GSK Investigational Site
    Philadelphia, Pennsylvania 19140, United States
  • GSK Investigational Site
    Austin, Texas 78705, United States
  • GSK Investigational Site
    Dallas, Texas 75246, United States
  • GSK Investigational Site
    Annandale, Virginia 22003, United States
09

References and documents

Publications

  • Akil B, Blick G, Hagins DP, Ramgopal MN, Richmond GJ, Samuel RM, Givens N, Vavro C, Song IH, Wynne B, Ait-Khaled M; VIKING-4 study team. Dolutegravir versus placebo in subjects harbouring HIV-1 with integrase inhibitor resistance associated substitutions: 48-week results from VIKING-4, a randomized study. Antivir Ther. 2015;20(3):343-8. doi: 10.3851/IMP2878. Epub 2014 Oct 16. PubMed 25321146 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2012 to primary completion in Oct 2012, 6 months.

Results were first posted in Feb 2014, 1 year 3 months after primary completion.

Of 57 industry-sponsored phase 3 interventional studies under HIV Infections, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 30. This study's 6 months is below that.

Counting every sponsor, half of 101 studies reached it within 27 months; a quarter within 20 and three quarters within 46.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 29, 2012
First posted
Apr 2, 2012
StartActual
Apr 18, 2012
Primary completionActual
Oct 31, 2012
CompletionActual
Dec 16, 2013
Results first posted
Feb 19, 2014
Last update
Jul 2, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 2, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01568892
Lead sponsor
ViiV Healthcare
Responsible party
Sponsor
First posted
Apr 2, 2012
Start date
Apr 18, 2012
Primary completion
Oct 31, 2012
Completion
Dec 16, 2013
Results posted
Feb 19, 2014
Last update
Jul 2, 2018

Study contacts

GSK Clinical Trials
study director · ViiV Healthcare

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dolutegravir

Start the discussion